KPLBSEKwality Pharmaceuticals LtdMediumNeutral
Announced Sat, 26 Jul · 18:26 IST

1. Appointment of Mr. Vinod Kumar Sharma as Additional, non executive Independent director of the company 2. Resignation of Mr. Kiran Kumar Verma as Independent director of the company 3. ....

Management Changes View source PDF

KPL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Kwality Pharmaceuticals has appointed Mr. Vinod Kumar Sharma as an Additional Non-Executive Independent Director for a 5-year term from July 26, 2025 to July 25, 2030, subject to shareholder approval. Separately, Mr. Kiran Kumar Verma has resigned as Independent Director effective July 26, 2025, citing other professional commitments, and has confirmed there are no other material reasons for his exit. Mr. Sharma brings over 33 years of pharmaceutical industry experience, having held senior roles (up to Sr. Vice President) at companies including Sun Pharma, Mankind Pharma, Alkem Labs, Unichem Labs, Dabur, and IPCA Labs. He is not related to any existing Director and is not debarred by SEBI. Following these changes, the Audit Committee and Nomination & Remuneration Committee have been reconstituted, with Mr. Sharma joining the Audit Committee as a member and taking over as Chairperson of the Nomination & Remuneration Committee.

Likely market impact

Routine board refreshment — one independent director replaced by another experienced pharma professional. No governance red flags or material impact expected on shareholders or stock price.